Glow-in-the-Dark dye could help surgeons spot brain tumors

NCT ID NCT07493447

Recruiting now Diagnosis Sponsor: Eben Rosenthal Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This early-stage trial tests a fluorescent dye called panitumumab-IRDye800 that attaches to cancer cells. Before surgery, 30 adults with brain tumors will receive a single infusion of the dye. During their operation, a special camera will detect the dye's glow, helping surgeons distinguish tumor tissue from healthy brain. The study primarily checks safety and whether the dye improves tumor visibility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Panitumumab-IRDye800 (a fluorescent dye that attaches to cancer cells)
What this could lead to: If it works, this could help surgeons see brain tumors more clearly during surgery, potentially leading to safer and more complete tumor removal.
What could go wrong: This is a very early, small pilot study with only 30 people. The dye may not work well for all tumor types, and there is a risk of side effects from the infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACOUSTIC NEUROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acoustic neuroma brain cancer glioblastoma meningioma neoplasm pituitary gland adenoma Pituitary Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACOUSTIC NEUROMA BRAIN CANCER GLIOBLASTOMA MENINGIOMA PITUITARY ADENOMA

Contacts and locations

Locations

Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232-0004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.